AI Article Synopsis
- HPV is a group of viruses that can lead to cancer when there's a long-lasting infection with high-risk types.
- Imiquimod is a topical treatment that boosts the immune system's response to fight tumors and viruses, but its effectiveness for HPV-related conditions in the lower genital tract is still being studied.
- This review highlights the current findings on how imiquimod works, its applications, results, and what factors might influence treatment success for HPV-induced lesions.
Article Abstract
Human papillomavirus (HPV) encompasses a group of viruses that infect the skin and mucous membranes. In the presence of certain factors, persistent infection with high-risk HPVs can trigger a process of neoplastic transformation. Imiquimod is a topical agent that acts as a Toll-like receptor 7/8 agonist, stimulating the innate and adaptive immune system to exert antitumor and antiviral effects. It has been approved for the treatment of various skin conditions, however, its efficacy and safety in the management of HPV-related-neoplasms of the lower genital tract, such as vulvar, vaginal, and cervical neoplasia, are still under investigation. This review summarizes the current evidence on the use of imiquimod for the treatment of HPV-induced lesions of the female lower genital tract, focusing on its indications, mechanisms of action, outcomes, and predictors of response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jmv.29238 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!